This blog is not affiliated or endorsed, by Nassau OTB, a public benefit corporation, subject to the New York Freedom
of Information Law, NY Pub Off Law Sec 84 et seq.
Tuesday, May 6, 2014
risks, benefits,alternatives
Mount Sinai may or may not have adequately disposed to Jay Patel and other trial participants, the risks, benefits or alternatives.
Life is all about money? Nothing else matters? Bet on it? Know what /why you are betting or just wing it?
effective and not sponsored by drug company errand people.
Let Dr. Emma Guttman-Yasky et al compare, contrast and debate the merits of their work with the work done overseas. See below. See also faustmanlab.org and pubmed.org.
It is an indictment of the intellects of Mount Sinai and Rockefeller University that BCG works for autoimmune diseases safely and inexpensively. These are things that drug companies do not much care for.
A corporation is a person without a soul and the people below are the corpulent embodiments of corporations?
BCG shoot it or shot someone else with it and see that it works and say I should have thought of that.
Mount Sinai dermatologist leading breakthrough treatment of severe eczema
Dr.
Emma Guttman-Yassky, an investigative researcher at the Icahn School of
Medicine at Mount Sinai Medical Center, is at the forefront of major
medical advances in the understanding and treatment of eczema. The
40-year-old rising star has identified molecules that cause the skin
disease and targeted drugs to treat it.
David Handschuh/New York Daily NewsDr.
Emma Guttman-Yassky, a star dermatologist at the Icahn School of
Medicine at Mount Sinai Medical Center, is at the forefront of
revolutionary treatments of severe eczema.
For the last three years, Neal Patel thought he was going to lose his
mind from itching — suffering through a skin condition that made for
miserable days and sleepless nights The 25-year-old medical student has
been tortured by severe eczema on and off since childhood.
In the latest flare-up, which began during his second year at Rutgers
New Jersey Medical School, he stopped dating and going out with friends,
embarrassed to be seen. Red scaly lesions erupted on his face, arms,
hands, trunk and legs. His bed sheets were bloodied from picking at his
skin for relief.
Until Dr. Emma Guttman-Yassky, a rising star dermatologist and
investigative researcher at the Icahn School of Medicine at Mount Sinai
Medical Center, came into his life.
Patel read about her groundbreaking research into atopic dermatitis, as
eczema is medically known, and called to see if he could enroll in one
of her ongoing clinical trials. “I am indebted to Dr. Guttman,” Patel
said. “She has pretty much saved my life.”
Dr. Emma Guttman-Yassky treats Neal Patel, a 25-year-old medical student that has suffered from severe eczema since childhood.
Guttman-Yassky, 40, is in the forefront of major advances in the
understanding and treatment of eczema. In her laboratory at Rockefeller
University and now at Mount Sinai, she has identified the molecules that
cause the inflammatory skin disease and targeted drugs to treat it.
She also discovered a unique lymphocyte “Th22” — and its possible role in atopic dermatitis.
“She really is changing the world,” said Dr. Mark Lebwohl, the chief of
dermatology at Mount Sinai and president of the American Academy of
Dermatology.
I am indebted to Dr. Guttman. She has pretty much saved my life.
Until now, the common treatments for severe eczema were powerful
systemic steroids, like prednisone, which can have terrible side
effects, and cyclosporine, a broad immune-suppressing drug that turns
off an entire immune system and can permanently damage the kidneys,
increase blood pressure and increase cancers.
The new drugs Guttman-Yassky is testing target only a very small part
of the immune system. If successful, they could be available to the
public within a few years.
Guttman-Yassky’s interest in internal medicine and dermatology has been
personal as well as professional. She herself had eczema as a child
growing up in Romania and Israel.
Neal Patel stopped dating and going out after his latest eczema flare-up.Enlarge
Eczema affects 30 million Americans, including 15% of the children in the U.S.Enlarge
“The molecular maps or pathways that are activated in eczema had not
been well defined,” Guttman-Yassky said. “It was not clear whether it
was a disease of immune activation or if the outer layer of the skin was
deficient. We now understand that the disease is primarily immune
driven ... which makes it much easier to cure.”
Guttman-Yassky is the principal investigator in several crucial drug
trials for patients with moderate to severe eczema — including one
funded by the National Institutes of Health for $2.7 million.
“I think these drugs could be a revolutionary change for patients who
have suffered for so long,” said Guttman-Yassky, who describes herself
as a medical Sherlock Holmes.
Eczema affects 30 million Americans, including 15% of the children in
the country. The good news is that most children will outgrow it by age
10 and many will outgrow it by age 5.
Patel, after just two weeks in the drug trial, is already seeing
progress. “I am clearing up, I am itching less, I am sleeping better,”
Patel said. “I haven’t felt this good in three years. I feel so lucky.”
>>> Rigshospitalet <news@meltwaterpress.com> 9/3/2012 9:27 AM >>>
Press release
3rd of September 2012
Tuberculosis vaccine - a new remedy for allergies and asthma in children? M Can a vaccine against tuberculosis help combat asthma
and eczema in Danish children early in life? This will now be examined
in a comprehensive Danish research study.
From September 2012, thousands of Danish pregnant women will receive an
invitation to allow their newborns to take part in a sensational trial.
The tuberculosis vaccine was removed from the vaccine program in Denmark
during the 1980s, however new research indicates that the vaccine can
improve the health of children.
Research carried out in developing countries shows that the health of
infants who have been given the tuberculosis vaccine (BCG/Calmette) at
birth is improved and the babies have a better survival rate than those
who have not been given the vaccine. The vaccine
also seems to have a preventive effect against asthma and atopic
dermatitis.
Results are so striking that they cannot be explained by the fact that
the children did not catch tuberculosis. Therefore, researchers assess
the vaccine to have a general positive effect on the immune system,
which means that children are less sick, and have
less atopic dermatitis, asthma and allergies.
Whether this positive effect also can benefit Danish children will now
be examined in a large Danish research project headed by Lone Graff
Stensballe, Paediatrician from the Department of Paediatrics and
Adolescent Medicine at Rigshospitalet.
The research project will run for three years, starting in September
2012, where 4,300 infants and their parents will be followed through
interviews, examinations, and, for 300 of the children, blood tests as
well. The project will comprise five PhD courses
and a research collaboration with obstetricians, paediatricians,
midwives, nurses and laboratory technicians from the three hospitals
taking part in the project.
“We are very excited about this unique opportunity to improve the health
of Danish children early in life,” says Lone Graff Stensballe.
“Unfortunately, we have seen large increases in admissions, consumption
of medicines, asthma, eczema and allergies among
Danish children. We hope to curb these increases with the new research
project.”
The research project will be carried out at Rigshospitalet in
collaboration with Hvidovre Hospital, Kolding Sygehus Lillebælt and the
new Centre for Vitamins and Vaccines at SSI (Statens Serum Institut).
For further information and interviews, please contact: Lone Graff Stensballe
Head of Research
Paediatrician, Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Denmark
Telephone: +45 6022 8092 E-mail:
lone.graff.stensballe@rh.regionh.dk
Rigshospitalet - a part of Copenhagen University Hospital
Rigshospitalet – a part of Copenhagen University Hospital – is
Denmark'sleading hospital for patients needing highly specialized
treatment. Rigshospitalet serves all of Denmark, Greenland and the Faroe
Islands within almost all specialties and sub-specialties
of medicine and surgery.
Afmelding: Ønsker du ikke længere at få tilsendt e-mails fra Rigshospitalet via Meltwater Press, venligst klik:
[her]. Afmelding kan tage op til 2 arbejdsdage.
Hvis du ønsker at kontakte Meltwater Press, kan du kontakte Meltwater Press på:
Meltwater Group Christian IX's Gade 10, 2. 1111 København K
--------------------------------------------------------
The information transmitted in this email and any of its attachments is
intended only for the person or entity to which it is addressed and may
contain information concerning Cablevision and/or its affiliates and
subsidiaries that is proprietary, privileged,
confidential and/or subject to copyright. Any review, retransmission,
dissemination or other use of, or taking of any action in reliance upon,
this information by persons or entities other than the intended
recipient(s) is prohibited and may be unlawful. If
you received this in error, please contact the sender immediately and
delete and destroy the communication and all of the attachments you have
received and all copies thereof.
--------------------------------------------------------
Denne e-mail indeholder fortrolig information. Hvis du ikke er den rette
modtager af denne e-mail eller hvis du modtager den ved en fejltagelse,
beder vi dig venligst informere afsender om fejlen ved at bruge
svarfunktionen. Samtidig bedes du slette e-mailen
med det samme uden at videresende eller kopiere den.
David Handschuh/New York Daily News Dr.
Emma Guttman-Yassky, a star dermatologist at the Icahn School of
Medicine at Mount Sinai Medical Center, is at the forefront of
revolutionary treatments of severe eczema. 
No comments:
Post a Comment